Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nasal Insulin IND

Executive Summary

California Biotechnology Inc. receives FDA approval for Phase I clinical testing on Nazlin, nasally administered insulin. The insulin product is the first to reach the IND stage for Cal Bio. Lilly has a letter of intent to develop and market the nasal formulation. Cal Bio Chairman William Baker commented that Cal Bio expects "to conclude commercial arrangements with Lilly on licensing of our Nazdel technology with insulin" following completion of Phase I work.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS009265

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel